Altimmune announces significant reductions in liver fat content and body weight in 12-week phase 1b clinical trial of pemvidutide in subjects with nafld

Gaithersburg, md., sept. 14, 2022 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week phase 1b study of pemvidutide1 in subjects with non-alcoholic fatty liver disease (nafld).

ALT Ratings Summary

ALT Quant Ranking